Danaher Corporation $DHR Stock Holdings Lowered by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 37.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 331,104 shares of the conglomerate’s stock after selling 195,664 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Danaher were worth $62,777,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Bank Pictet & Cie Europe AG grew its holdings in shares of Danaher by 25.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock worth $83,895,000 after acquiring an additional 74,301 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Danaher by 303.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after purchasing an additional 186,584 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new stake in shares of Danaher during the fourth quarter valued at $4,477,000. Legal & General Group Plc boosted its position in shares of Danaher by 1.0% in the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after purchasing an additional 43,169 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of Danaher by 220.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 674,373 shares of the conglomerate’s stock valued at $154,377,000 after purchasing an additional 463,764 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Analysts Set New Price Targets

Several analysts have issued reports on DHR shares. Morgan Stanley cut their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Wells Fargo & Company decreased their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday. HSBC dropped their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Barclays cut their price target on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, Guggenheim reduced their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $228.91.

Danaher Stock Down 0.3%

NYSE:DHR opened at $191.87 on Friday. The firm has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 2.38 and a beta of 0.79. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.52 and a debt-to-equity ratio of 0.48. The business’s fifty day moving average price is $185.64 and its 200 day moving average price is $197.04.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the business earned $0.77 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio is 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.